ELSEVIER

Blood 142 (2023) 7055–7056

The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

723.ALLOGENEIC TRANSPLANTATION: LONG-TERM FOLLOW-UP AND DISEASE RECURRENCE

Azacitidine Combined with Interferon α for Preemptive Treatment of AML/MDS after Allogeneic Peripheral Blood Stem Cell Transplantation:a Prospecitive Phase II Study

Chongmei Huang[1], *Jun Yang*[1], *Yin Tong*[1], *Huiying Qiu*[1], *Kun Zhou*[1], *Xinxin Xia*[2], *Ying Zhang*[2], *Chang Shen*[2], *Liping Wan*[1], *Xianmin Song, PhD*[2]

[1] Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
[2] Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Objective : this study investigated the efficacy and safety of azacitidine and interferon α preemptive treatment in the post-transplant in patients with AML/MDS. **Methods:** between Octorber 1, 2019 and July 31, 2022, a total of 49 patients aged 17 to 62 years were enrolled into this prospective clinical study of post-transplant azacitidine combined with interferon α preemptive treatment. Patients with minimal residual disease (MRD) positive and / or mixed chimerism were scheduled to receive azacitidine, given as 32 mg/m ^{2} per day subcutaneously for 5 days, and interferon α 3 million units/m ^{2} per day from 8th day and continued for 28th day for 1 cycle. **Results:** patients who acquired treatment response were 34 (69.4%), of which turned MRD-negative and obtained complete chimerism were 22 (44.9%) and 5 (10.2%) at 1 cycle, respectively. Median follow-up time after preemptive intervention was 440(range, 45 to 927) days. Cumulative incidences of relapse (CIR) and no relapse mortality (NRM) were 36.7% and 4.1%, respectively. Probabilities of event-free survival (EFS) and overall survival (OS) were 55.1% and 71.4%, respectively. The most common adverse events were graft-versus-host disease (GVHD) (38.8%), liver toxicity (46.9%) and neutropenia (28.6%). **Conclusion:** these data support the notion that azacitidine combined with interferon α is better used as the preemptive therapy against relapse tendency for patients after allo-HSCT performed for AML/MDS. Side effects were mainly GVHD, reversible cytopenia and hepatic toxicity. This prospective trial in the post-transplant setting was feasible and safe but challenging. This trial was registered at www.clinicaltrials.gov as#NCT04078399.

Disclosures No relevant conflicts of interest to declare.



Figure 1

https://doi.org/10.1182/blood-2023-179892